183 related articles for article (PubMed ID: 28511060)
1. A comparison study on RNase A oligomerization induced by cisplatin, carboplatin and oxaliplatin.
Picone D; Donnarumma F; Ferraro G; Gotte G; Fagagnini A; Butera G; Donadelli M; Merlino A
J Inorg Biochem; 2017 Aug; 173():105-112. PubMed ID: 28511060
[TBL] [Abstract][Full Text] [Related]
2. Platinated oligomers of bovine pancreatic ribonuclease: Structure and stability.
Picone D; Donnarumma F; Ferraro G; Russo Krauss I; Fagagnini A; Gotte G; Merlino A
J Inorg Biochem; 2015 May; 146():37-43. PubMed ID: 25756333
[TBL] [Abstract][Full Text] [Related]
3. Interactions of carboplatin and oxaliplatin with proteins: Insights from X-ray structures and mass spectrometry studies of their ribonuclease A adducts.
Messori L; Marzo T; Merlino A
J Inorg Biochem; 2015 Dec; 153():136-142. PubMed ID: 26239545
[TBL] [Abstract][Full Text] [Related]
4. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
5. Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group.
Mandal R; Kalke R; Li XF
Chem Res Toxicol; 2004 Oct; 17(10):1391-7. PubMed ID: 15487901
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of reaction of L-methionine with carboplatin and oxaliplatin in different media: a comparison with cisplatin.
Heudi O; Mercier-Jobard S; Cailleux A; Allain P
Biopharm Drug Dispos; 1999 Mar; 20(2):107-16. PubMed ID: 10206326
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability].
Chatelut E
Bull Cancer; 2011 Nov; 98(11):1253-61. PubMed ID: 22024542
[TBL] [Abstract][Full Text] [Related]
8. East-west fusion-necrosis and apoptosis acting in concert by demethylcantharidin-integrated platinum complexes.
Pang SK; So WK; Ho YP; Au-Yeung CF
Anticancer Agents Med Chem; 2014 Jun; 14(5):756-61. PubMed ID: 24476313
[TBL] [Abstract][Full Text] [Related]
9. Experimental study of renal disorder caused by oxaliplatin in rat renal cortical slices.
Kanou T; Uozumi J; Soejima K; Tokuda Y; Masaki Z
Clin Exp Nephrol; 2004 Dec; 8(4):310-5. PubMed ID: 15619029
[TBL] [Abstract][Full Text] [Related]
10. Structural and functional evaluation of interaction between mammalian ribosomal RNA with platinum-containing antineoplastic drugs.
Theile D; Kos M
Toxicol Lett; 2016 Feb; 242():47-52. PubMed ID: 26656794
[TBL] [Abstract][Full Text] [Related]
11. Picoplatin binding to proteins: X-ray structures and mass spectrometry data on the adducts with lysozyme and ribonuclease A.
Ferraro G; Lyčková T; Massai L; Štarha P; Messori L; Merlino A
Dalton Trans; 2024 May; 53(20):8535-8540. PubMed ID: 38727007
[TBL] [Abstract][Full Text] [Related]
12. Will the Interactions of Some Platinum (II)-Based Drugs with B-Vitamins Reduce Their Therapeutic Effect in Cancer Patients? Comparison of Chemotherapeutic Agents such as Cisplatin, Carboplatin and Oxaliplatin-A Review.
Szefler B; Czeleń P
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675064
[TBL] [Abstract][Full Text] [Related]
13. Poly (γ, L-glutamic acid)-cisplatin bioconjugate exhibits potent antitumor activity with low toxicity: a comparative study with clinically used platinum derivatives.
Feng Z; Lai Y; Ye H; Huang J; Xi XG; Wu Z
Cancer Sci; 2010 Nov; 101(11):2476-82. PubMed ID: 20813014
[TBL] [Abstract][Full Text] [Related]
14. Joint forces of mass spectrometric techniques (ICP-MS and MALDI-TOF-MS) and fluorescence spectrometry in the study of platinum-based cytostatic drugs interactions with metallothionein MT2 and MT3.
Pavelicova K; Do T; Vejvodova M; Vaculovic T; Nowak K; Matczuk M; Wu S; Krężel A; Adam V; Vaculovicova M
Talanta; 2024 Jul; 274():125920. PubMed ID: 38574532
[TBL] [Abstract][Full Text] [Related]
15. Modification of the physicochemical and pharmacological properties of anticancer platinum compounds by commercial 5-fluorouracil formulations: a comparative study using cisplatin and carboplatin.
Fournier C; Hecquet B; Bastian G; Khayat D
Cancer Chemother Pharmacol; 1992; 29(6):461-6. PubMed ID: 1568289
[TBL] [Abstract][Full Text] [Related]
16. Exploring binding affinity of oxaliplatin and carboplatin, to nucleoprotein structure of chromatin: spectroscopic study and histone proteins as a target.
Soori H; Rabbani-Chadegani A; Davoodi J
Eur J Med Chem; 2015 Jan; 89():844-50. PubMed ID: 25462284
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin.
Mohammed MQ; Retsas S
Anticancer Drugs; 2000 Nov; 11(10):859-63. PubMed ID: 11142694
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous translocation of antitumor oxaliplatin, its enantiomeric analogue, and Cisplatin from one strand to another in double-helical DNA.
Malina J; Natile G; Brabec V
Chemistry; 2013 Sep; 19(36):11984-91. PubMed ID: 23873652
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond E; Faivre S; Woynarowski JM; Chaney SG
Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS.
Curis E; Provost K; Bouvet D; Nicolis I; Crauste-Manciet S; Brossard D; Bénazeth S
J Synchrotron Radiat; 2001 Mar; 8(Pt 2):716-8. PubMed ID: 11512906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]